 RADNOR, Pa., Oct. 14, 2021 PRNewswire -- NRx Pharmaceuticals Nasdaq: NRXP, today announced the publication of peer-reviewed results from a prospective, open-label, administratively controlled trial of aviptadil for the treatment of respiratory failure in patients with Critical COVID-19. 